Arrow
use cases

AI Driven Precision in Predicting and Treating Hematologic Cancer

Prediction of hematologic cancers through AI to enhance the precision and efficiency in early detection and management of blood cancers.

Problem

Hematological cancers, such as leukemias, lymphomas and myelomas, manifest from blood-forming tissues and their prognosis largely depends on both the cancer subtype and its stage at the time of detection. These cancers, characterized by subtle and non-specific initial symptoms, are quite difficult to diagnose in their early stages, although early identification is critical to optimize treatment success and improve survival prospects. In 2020, approximately 1.2 million people were fighting these blood cancers or were in remission, representing an alarming 9.5% of newly diagnosed cancer cases in the United States (1)(2). Survival rates vary widely, from around 60% in leukemias to more than 85% in specific lymphomas, emphasizing the dire need for timely and accurate detection and treatment (3)(4).

Why it matters

  • Hematological cancers are difficult to diagnose early due to subtle and non-specific symptoms.
  • In 2020, 9.5% of new cancer cases in the U.S. were hematological cancers, affecting 1.2 million people.
  • Survival rates vary: about 60% for leukemias and over 85% for certain lymphomas.

Solution

"HemaSupport AI”, A conversational AI assistant to provide decision support based on the most current research and clinical guidelines.

Discover more and interact with our AI!

Datasources

Integrates guidelines from the European Hematology Association (5), which detail care standards, findings from Allart-Vorelli et al. (6) on quality of life in blood cancer, and NICE directives (7).

Citations

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.
  2. Epub 2021 Feb 4. PMID: 33538338.2. Yuan J, Zhang Y, Wang X. Application of machine learning in the management of lymphoma: Current practice and future prospects. Digit Health. 2024 Apr 16;10:20552076241247963. doi: 10.1177/20552076241247963. PMID: 38628632; PMCID: PMC11020711.3.
  3. Jiménez Pérez M, Grande RG. Application of artificial intelligence in the diagnosis and treatment of hepatocellular carcinoma: A review. World J Gastroenterol. 2020 Oct 7;26(37):5617-5628. doi: 10.3748/wjg.v26.i37.5617. PMID: 33088156; PMCID: PMC7545389.4.
  4. El Alaoui Y, Elomri A, Qaraqe M, Padmanabhan R, Yasin Taha R, El Omri H, El Omri A, Aboumarzouk O. A Review of Artificial Intelligence Applications in Hematology Management: Current Practices and Future Prospects. J Med Internet Res. 2022 Jul 12;24(7):e36490. doi: 10.2196/36490. PMID: 35819826; PMCID: PMC9328784.5.
  5. Allart-Vorelli, P., Porro, B., Baguet, F., Michel, A., & Cousson-Gélie, F. (2015). Haematological cancer and quality of life: a systematic literature review. Blood Cancer Journal, 5(4), e305. https://doi.org/10.1038/bcj.2015.29‍
  6. The European Hematology Association (EHA). (n.d.). Clinical practice guidelines. Retrieved from https://ehaweb.org/guidelines/clinical-practice-guidelines/‍
  7. National Institute for Health and Care Excellence (NICE). (2016). Haematological cancers: improving outcomes. (NICE Guideline, No. 47). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK367648/

Problem

Hematological cancers, such as leukemias, lymphomas and myelomas, manifest from blood-forming tissues and their prognosis largely depends on both the cancer subtype and its stage at the time of detection. These cancers, characterized by subtle and non-specific initial symptoms, are quite difficult to diagnose in their early stages, although early identification is critical to optimize treatment success and improve survival prospects. In 2020, approximately 1.2 million people were fighting these blood cancers or were in remission, representing an alarming 9.5% of newly diagnosed cancer cases in the United States (1)(2). Survival rates vary widely, from around 60% in leukemias to more than 85% in specific lymphomas, emphasizing the dire need for timely and accurate detection and treatment (3)(4).

Problem Size

  • Hematological cancers are difficult to diagnose early due to subtle and non-specific symptoms.
  • In 2020, 9.5% of new cancer cases in the U.S. were hematological cancers, affecting 1.2 million people.
  • Survival rates vary: about 60% for leukemias and over 85% for certain lymphomas.

Solution

"HemaSupport AI”, A conversational AI assistant to provide decision support based on the most current research and clinical guidelines.

Opportunity Cost


Impact


Data Sources

Integrates guidelines from the European Hematology Association (5), which detail care standards, findings from Allart-Vorelli et al. (6) on quality of life in blood cancer, and NICE directives (7).


References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.
  2. Epub 2021 Feb 4. PMID: 33538338.2. Yuan J, Zhang Y, Wang X. Application of machine learning in the management of lymphoma: Current practice and future prospects. Digit Health. 2024 Apr 16;10:20552076241247963. doi: 10.1177/20552076241247963. PMID: 38628632; PMCID: PMC11020711.3.
  3. Jiménez Pérez M, Grande RG. Application of artificial intelligence in the diagnosis and treatment of hepatocellular carcinoma: A review. World J Gastroenterol. 2020 Oct 7;26(37):5617-5628. doi: 10.3748/wjg.v26.i37.5617. PMID: 33088156; PMCID: PMC7545389.4.
  4. El Alaoui Y, Elomri A, Qaraqe M, Padmanabhan R, Yasin Taha R, El Omri H, El Omri A, Aboumarzouk O. A Review of Artificial Intelligence Applications in Hematology Management: Current Practices and Future Prospects. J Med Internet Res. 2022 Jul 12;24(7):e36490. doi: 10.2196/36490. PMID: 35819826; PMCID: PMC9328784.5.
  5. Allart-Vorelli, P., Porro, B., Baguet, F., Michel, A., & Cousson-Gélie, F. (2015). Haematological cancer and quality of life: a systematic literature review. Blood Cancer Journal, 5(4), e305. https://doi.org/10.1038/bcj.2015.29‍
  6. The European Hematology Association (EHA). (n.d.). Clinical practice guidelines. Retrieved from https://ehaweb.org/guidelines/clinical-practice-guidelines/‍
  7. National Institute for Health and Care Excellence (NICE). (2016). Haematological cancers: improving outcomes. (NICE Guideline, No. 47). Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK367648/

Book a Free Consultation

Trusted by the world's top healthcare institutions